Epilepsy is a neurological disorder in which patient experiences epileptic seizures. These epileptic seizures are a result of the disturbance in the electrical communication in neurons. Seizures can vary from short period to long episodes of vigorous shaking. Epilepsy can be diagnosed in a patient only after one or more seizure episodes. Patients may have more than one type of seizure and these seizures usually follow the same pattern each time they occur to the patient. Causes of epilepsy include patients genetics, tumor or brain injuries. Epileptic seizures are of two types, i.e. focal and generalized depending on the affected area of the brain. Symptoms which occur before seizures include nausea, headache, strange feeling and visual loss. Anti-epileptic drugs are used to treat this neurological disorder.
This market analysis report on anti-epileptic drugs market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiative and decision making. The report provides market value and forecast for the anti-epileptic drugs market.
The scope of the report comprises demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminostilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA- vinyl - GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxy barbiturate, phenyltriazine, nicotinic acid derivatives and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of anti-epileptic drugs market. CAGRs are provided for the forecast year 2022-2030 for each segment.
This report provides key insights about the global anti-epileptic drugs market including market drivers & restraints, key trends, opportunities, and regional outlook. Analysis tools such as Porter’s five forces along with competitive landscape analysis are also incorporated in this report. Leading players in the global anti-epileptic market are also profiled in this report. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.
A complete description is also presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which hold prominent position in the anti-epileptic drugs market globally. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.
Anti-epileptic drugs are classified based on the drug class. Each drug class has different mechanism of action for the treatment of epilepsy. Due to difference in mechanism of action, prescription of the drug depends on the type of seizures occurring to the patients. Most of the drugs are used as monotherapy and for partial onset seizures. Succinimides, hydantoin derivatives and benzodiazepines are mostly preferred by the doctorsVimpat, Fycompa, Lacosamide and Retigabine are some of the ant-epileptic drugs preferred by the physicians.
Increasing awareness about treatment with anti-epileptic drugs, patent expiration and approval of pipeline products are the factors responsible for the market growth. The global anti-epileptic drugs market is emerging at considerable pace because of high prevalence of epilepsy and more research and development activities involved.
Geographically, the global anti-epileptic drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.
According to the estimation for the year 2020, North America dominated the global anti-epileptic drugs market by accounting major market share. In terms of market share, North America is followed by Europe. Increased healthcare expenditure, government initiatives and approval of new drugs are the prime factors regulating the market in these regions. For instance, a few years back, Eisai Co. Ltd. has launched Fycompa in Americas and Europe. Other factors for the market growth in this region include high prevalence of epilepsy and presence of treatment options in the region. According to the research, there are around 2.5 million cases of epilepsy in the U.S. and around 15,000 new cases of epilepsy are diagnosed each year in Canada. In terms of market value, Europe is followed by Asia Pacific. Due to the high prevalence of epilepsy in China and India and increased awareness of epilepsy are some of the major factors responsible for anti-epileptic drugs market growth.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
This market analysis report on anti-epileptic drugs market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiative and decision making. The report provides market value and forecast for the anti-epileptic drugs market.
The scope of the report comprises demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminostilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA- vinyl - GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxy barbiturate, phenyltriazine, nicotinic acid derivatives and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of anti-epileptic drugs market. CAGRs are provided for the forecast year 2022-2030 for each segment.
This report provides key insights about the global anti-epileptic drugs market including market drivers & restraints, key trends, opportunities, and regional outlook. Analysis tools such as Porter’s five forces along with competitive landscape analysis are also incorporated in this report. Leading players in the global anti-epileptic market are also profiled in this report. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.
A complete description is also presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which hold prominent position in the anti-epileptic drugs market globally. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.
Anti-epileptic drugs are classified based on the drug class. Each drug class has different mechanism of action for the treatment of epilepsy. Due to difference in mechanism of action, prescription of the drug depends on the type of seizures occurring to the patients. Most of the drugs are used as monotherapy and for partial onset seizures. Succinimides, hydantoin derivatives and benzodiazepines are mostly preferred by the doctorsVimpat, Fycompa, Lacosamide and Retigabine are some of the ant-epileptic drugs preferred by the physicians.
Increasing awareness about treatment with anti-epileptic drugs, patent expiration and approval of pipeline products are the factors responsible for the market growth. The global anti-epileptic drugs market is emerging at considerable pace because of high prevalence of epilepsy and more research and development activities involved.
Geographically, the global anti-epileptic drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.
According to the estimation for the year 2020, North America dominated the global anti-epileptic drugs market by accounting major market share. In terms of market share, North America is followed by Europe. Increased healthcare expenditure, government initiatives and approval of new drugs are the prime factors regulating the market in these regions. For instance, a few years back, Eisai Co. Ltd. has launched Fycompa in Americas and Europe. Other factors for the market growth in this region include high prevalence of epilepsy and presence of treatment options in the region. According to the research, there are around 2.5 million cases of epilepsy in the U.S. and around 15,000 new cases of epilepsy are diagnosed each year in Canada. In terms of market value, Europe is followed by Asia Pacific. Due to the high prevalence of epilepsy in China and India and increased awareness of epilepsy are some of the major factors responsible for anti-epileptic drugs market growth.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anti-epileptic Drugs market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Anti-epileptic Drugs market and their expected impact during the forecast period.
Market Segmentation
Drug Class
- Hydantoin derivatives
- Phenytoin
- Fosphenytoin
- Iminostilbenes
- Carbamazepine
- Oxcarbazepine
- Long acting barbiturates
- Phenobarbitone
- Methobarbitone
- Succinimides
- Ethosuximide
- Methsuximide
- Phensuximide
- Benzodiazepines
- Clonazepam
- Nitrazepam
- Diazepam
- Carbonic anhydrase inhibitors (CAI)
- Acetazolamide
- Sulthiame
- GAMA- vinyl - GABA
- Vigabatrin
- Amino acid derivatives
- GABA pentin
- Monosaccharide derivatives
- Topiramate
- Others
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Anti-epileptic Drugs market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Anti-epileptic Drugs market?
- Which is the largest regional market for Anti-epileptic Drugs market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Anti-epileptic Drugs market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-epileptic Drugs market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Anti-epileptic Drugs Market: Competitive Analysis
4. Anti-epileptic Drugs Market: Macro Analysis & Market Dynamics
5. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)
6. North America Anti-epileptic Drugs Market, 2020-2030, USD (Million)
7. UK and European Union Anti-epileptic Drugs Market, 2020-2030, USD (Million)
8. Asia Pacific Anti-epileptic Drugs Market, 2020-2030, USD (Million)
9. Latin America Anti-epileptic Drugs Market, 2020-2030, USD (Million)
10. Middle East and Africa Anti-epileptic Drugs Market, 2020-2030, USD (Million)
11. Company Profile
List of Figures
List of Tables
Companies Mentioned
- Abide Therapeutics
- Advicenne Pharma SA
- Alexza Pharmaceuticals
- Argentum Pharmaceuticals
- GlaxoSmithKline (GSK) plc
- GW Pharmaceuticals Plc
- Janssen Pharmaceuticals
- Marinus Pharmaceuticals
- Novartis Pharmaceuticals Corp
- Otsuka Pharmaceuticals
- Pfizer Inc.
- Takeda Pharmaceutical Company Ltd
- UCB Pharma
